GB201719447D0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB201719447D0
GB201719447D0 GBGB1719447.3A GB201719447A GB201719447D0 GB 201719447 D0 GB201719447 D0 GB 201719447D0 GB 201719447 A GB201719447 A GB 201719447A GB 201719447 D0 GB201719447 D0 GB 201719447D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1719447.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB1719447.3A priority Critical patent/GB201719447D0/en
Publication of GB201719447D0 publication Critical patent/GB201719447D0/en
Priority to SG11202004601YA priority patent/SG11202004601YA/en
Priority to EA202091295A priority patent/EA202091295A1/ru
Priority to IL274719A priority patent/IL274719B2/en
Priority to EP18807571.7A priority patent/EP3713602A1/en
Priority to RU2020120547A priority patent/RU2020120547A/ru
Priority to CN201880075625.0A priority patent/CN111511399A/zh
Priority to JP2020527951A priority patent/JP6955632B2/ja
Priority to MYPI2020002408A priority patent/MY194682A/en
Priority to US16/765,786 priority patent/US11857625B2/en
Priority to PCT/EP2018/081129 priority patent/WO2019101582A1/en
Priority to MX2020004747A priority patent/MX2020004747A/es
Priority to AU2018371056A priority patent/AU2018371056B2/en
Priority to CA3082832A priority patent/CA3082832C/en
Priority to BR112020009866-3A priority patent/BR112020009866A2/pt
Priority to KR1020207017469A priority patent/KR102767553B1/ko
Priority to ARP180103417A priority patent/AR113534A1/es
Priority to CL2020001307A priority patent/CL2020001307A1/es
Priority to CONC2020/0006120A priority patent/CO2020006120A2/es
Priority to US18/394,323 priority patent/US20240123065A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB1719447.3A 2017-11-23 2017-11-23 Pharmaceutical composition Ceased GB201719447D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1719447.3A GB201719447D0 (en) 2017-11-23 2017-11-23 Pharmaceutical composition
KR1020207017469A KR102767553B1 (ko) 2017-11-23 2018-11-13 제제
MYPI2020002408A MY194682A (en) 2017-11-23 2018-11-13 Formulation
PCT/EP2018/081129 WO2019101582A1 (en) 2017-11-23 2018-11-13 Formulation
IL274719A IL274719B2 (en) 2017-11-23 2018-11-13 Formulation
EP18807571.7A EP3713602A1 (en) 2017-11-23 2018-11-13 Formulation
RU2020120547A RU2020120547A (ru) 2017-11-23 2018-11-13 Препарат
CN201880075625.0A CN111511399A (zh) 2017-11-23 2018-11-13 制剂
JP2020527951A JP6955632B2 (ja) 2017-11-23 2018-11-13 製剤
SG11202004601YA SG11202004601YA (en) 2017-11-23 2018-11-13 Formulation
US16/765,786 US11857625B2 (en) 2017-11-23 2018-11-13 Pharmaceutical compositions
EA202091295A EA202091295A1 (ru) 2017-11-23 2018-11-13 Препарат
MX2020004747A MX2020004747A (es) 2017-11-23 2018-11-13 Formulacion.
AU2018371056A AU2018371056B2 (en) 2017-11-23 2018-11-13 Formulation
CA3082832A CA3082832C (en) 2017-11-23 2018-11-13 Formulation
BR112020009866-3A BR112020009866A2 (pt) 2017-11-23 2018-11-13 formulação
ARP180103417A AR113534A1 (es) 2017-11-23 2018-11-22 Formulación
CL2020001307A CL2020001307A1 (es) 2017-11-23 2020-05-18 Formulación.
CONC2020/0006120A CO2020006120A2 (es) 2017-11-23 2020-05-18 Formulación
US18/394,323 US20240123065A1 (en) 2017-11-23 2023-12-22 Pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1719447.3A GB201719447D0 (en) 2017-11-23 2017-11-23 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
GB201719447D0 true GB201719447D0 (en) 2018-01-10

Family

ID=60950516

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1719447.3A Ceased GB201719447D0 (en) 2017-11-23 2017-11-23 Pharmaceutical composition

Country Status (19)

Country Link
US (2) US11857625B2 (https=)
EP (1) EP3713602A1 (https=)
JP (1) JP6955632B2 (https=)
KR (1) KR102767553B1 (https=)
CN (1) CN111511399A (https=)
AR (1) AR113534A1 (https=)
AU (1) AU2018371056B2 (https=)
BR (1) BR112020009866A2 (https=)
CA (1) CA3082832C (https=)
CL (1) CL2020001307A1 (https=)
CO (1) CO2020006120A2 (https=)
EA (1) EA202091295A1 (https=)
GB (1) GB201719447D0 (https=)
IL (1) IL274719B2 (https=)
MX (1) MX2020004747A (https=)
MY (1) MY194682A (https=)
RU (1) RU2020120547A (https=)
SG (1) SG11202004601YA (https=)
WO (1) WO2019101582A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN113769082A (zh) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 抗il-17a抗体药物组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
MX362591B (es) * 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
SG10201510762YA (en) * 2011-01-14 2016-01-28 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
PE20150190A1 (es) * 2012-06-21 2015-02-13 Ucb Pharma Sa Formulacion farmaceutica
CN107148283A (zh) * 2014-10-31 2017-09-08 豪夫迈·罗氏有限公司 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
MY206805A (en) 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
US20190060241A1 (en) 2016-04-13 2019-02-28 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
KR102329490B1 (ko) 2016-09-14 2021-11-23 베이징 한미 파마슈티컬 컴퍼니 리미티드 Ｉｌ-１７ａ에 특이적으로 결합하는 항체 및 그의 기능성 단편

Also Published As

Publication number Publication date
BR112020009866A2 (pt) 2020-11-17
AU2018371056A1 (en) 2020-06-04
MY194682A (en) 2022-12-14
JP6955632B2 (ja) 2021-10-27
CA3082832A1 (en) 2019-05-31
JP2021504321A (ja) 2021-02-15
CA3082832C (en) 2023-07-18
EA202091295A1 (ru) 2020-09-03
EP3713602A1 (en) 2020-09-30
AR113534A1 (es) 2020-05-13
AU2018371056B2 (en) 2024-06-20
CO2020006120A2 (es) 2020-05-29
IL274719A (en) 2020-07-30
WO2019101582A1 (en) 2019-05-31
RU2020120547A (ru) 2021-12-23
US11857625B2 (en) 2024-01-02
KR20200090829A (ko) 2020-07-29
MX2020004747A (es) 2020-08-20
US20210106683A1 (en) 2021-04-15
KR102767553B1 (ko) 2025-02-12
RU2020120547A3 (https=) 2021-12-23
CL2020001307A1 (es) 2020-10-16
IL274719B1 (en) 2024-06-01
US20240123065A1 (en) 2024-04-18
SG11202004601YA (en) 2020-06-29
CN111511399A (zh) 2020-08-07
IL274719B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
IL265260B (en) pharmaceutical preparations
IL265360B (en) Pharmaceutical composition
IL271986A (en) pharmaceutical preparation
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL262654A (en) Pharmacy preparation
IL265349A (en) Pharmaceutical composition
GB201712159D0 (en) Pharmaceutical composition
GB201705303D0 (en) Pharmaceutical compositions
HUE068810T2 (hu) Gyógyászati készítmény
GB201705304D0 (en) Pharmaceutical compositions
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
GB201713660D0 (en) Pharmaceutical compositions
GB201705305D0 (en) Pharmaceutical compositions
GB201705306D0 (en) Pharmaceutical compositions
PL3646867T3 (pl) Kompozycja farmaceutyczna
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615917D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
IL271513A (en) Innovative pharmaceutical composition
IL265436B (en) Pharmacy preparation
GB201615910D0 (en) Pharmaceutical composition
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition
GB201708329D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)